Nuvation Bio
NUVB
124 hedge funds and large institutions have $490M invested in Nuvation Bio in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 42 increasing their positions, 38 reducing their positions, and 17 closing their positions.
1,955% more call options, than puts
Call options by funds: $226K | Put options by funds: $11K
142% more capital invested
Capital invested by funds: $203M → $490M (+$287M)
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
11% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 38
7% more funds holding
Funds holding: 116 → 124 (+8)
0.43% more ownership
Funds ownership: 61.32% → 61.75% (+0.43%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.08M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.57M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.2M |
| 4 |
Barclays
London,
United Kingdom
|
+$2.15M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.21M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$3.46M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$1.92M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.69M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.13M |
NUVB Hedge Fund Activity: Q1 2024 in Review
124 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q1 2024, worth a combined $490M — up 142% from $203M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new NUVB positions and 17 closed out — a net gain of 10 holders — while 42 added to existing stakes and 38 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $3.08M. The largest seller was Millennium Management, cutting an estimated $4.21M.
- 124 institutional investors held Nuvation Bio (NUVB) as of Q1 2024, up from 116 in Q4 2023.
- Funds reported $490M of Nuvation Bio stock for Q1 2024, up 142% quarter-over-quarter.
- 27 funds opened new Nuvation Bio positions in Q1 2024 and 17 closed out, a net change of +10 holders.
- The largest Nuvation Bio buyer in Q1 2024 was Fidelity Investments, an estimated $3.08M added.
- The largest Nuvation Bio seller in Q1 2024 was Millennium Management, an estimated $4.21M sold.
Based on aggregated 13F filings for Q1 2024.